The FDA has approved a 30-minute onset of action for Novartis' Focalin XR (dexmethylphenidate HCl extended-release capsules) for the treatment of children with attention deficit hyperactivity disorder (ADHD). In a double-blind, crossover trial of 86 patients between 6-12 years of age, those treated with Focalin XR had significant improvements in attention, deportment, and academic productivity at 30 minutes post-dose compared to placebo.

For more information call (888) NOW-NOVA or visit www.focalinxr.com.